drugset / Trial / NCT03231969
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
Timeline
- Start
- 2017-07-20
- Primary completion
- 2017-10-11
- Completion
- 2017-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bilastine | Small molecule | 0.2 % | Other |
| Subject | Bilastine | Small molecule | 0.4 % | Other |
| Subject | Bilastine | Small molecule | 0.6 % | Other |